Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. - Wikidata - wikimedia - TriplyDB

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

http://www.wikidata.org/entity/Q30438159

about

Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Peptide-based vaccines for cancer therapy Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.Long-term outcomes of helper peptide vaccination for metastatic melanoma.Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.Fusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responses The Goldilocks model for TCR-too much attraction might not be best for vaccine design Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells.Profound tumor-specific Th2 bias in patients with malignant glioma.The immune response to tumors as a tool toward immunotherapy.Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo Therapeutic cancer vaccines: are we there yet?Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics.Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma Multipeptide vaccination in cancer patients.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.Melanoma immunotherapy: historical precedents, recent successes and future prospects.Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies.Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.

P2860

Q26796314-3EA99793-6711-47E3-87A4-C6B8CC584DF8 Q27022312-507B45E1-5E30-4E6F-B306-C3254967DDE2 Q28067023-0FD1CF7B-CF93-477E-8B45-5BFA750CAF02 Q30275159-D24CCEFC-87A7-490F-975F-4B13E1DE8CD4 Q30278070-4B5AF368-CFB7-4305-A6B3-890C698933E0 Q30278874-8FB48AFF-EB4A-4904-A0AE-8A791021C576 Q30299957-08920D41-D269-4959-A963-4E6EA61F4849 Q30370026-64F3D51B-31CD-451A-8390-1359A369EBBB Q30370848-14BEE34F-B23A-4F2C-BF8F-440507EA2C80 Q30371547-08D7A316-4739-49E4-8196-BFDAEA155ADD Q30411269-68A08342-A591-4858-B534-4B1B63B1E2AB Q30411499-9C701376-460E-4852-B755-5C7C23BDA147 Q30412106-3BFD8DF3-6516-46DD-A375-59CF9CA45BF2 Q30414395-88E7DD3E-828B-46FA-B964-97BE1A636FD1 Q30423165-36C4D0F4-F34D-46AF-A525-70B31538819F Q30425111-74D400FD-A214-4752-A41F-CB5BA5111FEB Q30425914-2CBC3DCE-A398-4A53-810C-32160E8A9FDF Q30426385-066DD85B-BFE3-4836-951F-BECFF43AA150 Q30429708-B233C5B2-213B-4D9E-A8B0-8E76FCD228E7 Q30430002-316B7C0D-4947-4EEC-A33D-036DB347D816 Q30434822-7FD4769D-440E-48E5-9141-0338E16428ED Q30436792-AE790AF3-A246-48E1-AB13-5131721C2378 Q33643966-FBD340C1-7D9B-4DF8-875A-F0A3C5616FE6 Q33698006-2F9AFC0B-5B6E-4E40-8B48-9248BF3DCA01 Q33907628-623AE4FE-8BE5-449C-9D51-7E8346A5A62D Q34138324-4D3F6680-1C61-4802-9424-3B707FAF2772 Q34329143-73CE29C5-50CB-45FE-9B0B-B0983AA543CE Q34491734-559083B4-FF9C-4CD4-B87F-3F4824B8D113 Q34634545-6CC03595-0B87-4D0C-93FC-B791730A69B7 Q34666875-3AC212D3-F2D4-4022-B32D-D21A96158A27 Q34786691-BEECB4FD-87F4-41B2-9AC2-F9F1F622F5B6 Q35155933-12EB5587-546B-4B5E-88D7-121B50AFF768 Q35234354-CD2BEF24-980A-4D82-99DF-720A45365FC4 Q37547268-85E20DE4-7506-46E7-92E9-ED746549EF29 Q37737327-186EB466-A465-4A1B-90B0-66BEA887CDF2 Q37762274-917B5A20-4954-44FA-986C-815458C13A66 Q37801939-C1909995-1F04-4A7F-9435-2A4D455734B5 Q38081911-E33620A5-F48E-458E-BF36-3D3223269B48 Q38196935-3747F467-531B-49B0-AC4C-5236A5A4041F Q38261273-269D58A3-B3C0-493A-8911-59E762760269

P2860

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

http://www.wikidata.org/entity/Q30438159

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Helper T-cell responses and cl ...... ytic differentiation antigens.

@ast

Helper T-cell responses and cl ...... ytic differentiation antigens.

@en

type

label

Helper T-cell responses and cl ...... ytic differentiation antigens.

@ast

Helper T-cell responses and cl ...... ytic differentiation antigens.

@en

prefLabel

Helper T-cell responses and cl ...... ytic differentiation antigens.

@ast

Helper T-cell responses and cl ...... ytic differentiation antigens.

@en

P1433

Q30438159-4F36A86E-CB88-4E83-8601-2634AF5D83AB

P1476

Q30438159-27908ED3-C42C-4C5B-9FDE-2672BBF59BD3

P2093

Q30438159-08F88CAA-584D-47CD-AD75-A0556F88FA9E

Q30438159-506F1D5D-A03E-4FC2-A37B-291DBB1EE646

Q30438159-553A36DE-B90D-4F65-9630-49522B2877D8

Q30438159-62FF77F9-FED8-41EC-AD74-6A637FBB0F1E

Q30438159-6BA87880-4C22-444B-8A97-0C689E09B1B8

Q30438159-7AD1B7F6-93A8-43B7-BF0B-148815B7C2AC

Q30438159-A60D8076-A192-4978-9497-46E8D6BD3832

Q30438159-B2EFB34D-54C9-4D6B-8877-C759182F0B2E

Q30438159-B530D158-02D6-4D45-9686-4DA1E83F5B36

Q30438159-B916F068-38A0-4DA9-8B43-4E2F60A1FB12

P2860

Q30438159-252284B1-CF20-4ACF-9413-5433690CD785

Q30438159-3792C064-C039-4E3F-8DC1-3A49DAEE4E30

Q30438159-3CB5E3F9-F1DB-4A8F-B28E-4D3C364C3406

Q30438159-44EA4432-D4AD-4BD0-8C0E-0D522A6B3457

Q30438159-4E944C1E-5F3E-485F-A6F2-1E75952B6B3A

Q30438159-52421953-FEDA-4469-A159-EE3B94754AB4

Q30438159-5C5A56B0-A636-44DC-A68B-969F754C7192

Q30438159-83C7B59D-688A-4F45-ADEF-3EB7A6DCB9EF

Q30438159-83ECE287-FE16-46B2-8C0C-BC797C761429

Q30438159-9E1F701E-AA06-4C06-8D05-D8061C1E7E70

P304

Q30438159-BCF52BF2-3619-4DC3-A188-0ACB4B197F79

P31

Q30438159-8C2BB44E-9B09-488B-93A5-54DECF14438B

P356

Q30438159-ADEC8A2A-3CD9-45A3-8127-5F1587E7AD50

P407

Q30438159-B163DD18-FF0E-451B-A46D-FAE6B0B25DBB

P433

Q30438159-8B68089D-7F49-4908-9115-7CD7D6403129

P478

Q30438159-4C39E243-49B2-413B-998A-DF26D7CF4F3A

P50

Q30438159-316315F6-7CA5-4632-8323-7D7CF7B21515

Q30438159-62C11922-9BD8-490B-88D1-E571FEA75B8C

P577

Q30438159-F2B40BF0-9A70-4596-BC5A-7C0F22421559

P698

Q30438159-398593EA-4B59-463C-A356-25CB03CF3A33

P932

Q30438159-9B70187C-AE9D-458B-A459-3215DE0358F7

P356

JCO.2008.17.3161

P1433

Journal of Clinical Oncology

P1476

Helper T-cell responses and cl ...... ytic differentiation antigens.

@en

P2093

Andrea Czarkowski

http://www.w3.org/2001/XMLSchema#string

Carmel Nail

http://www.w3.org/2001/XMLSchema#string

Donna H Deacon

http://www.w3.org/2001/XMLSchema#string

Gina R Petroni

http://www.w3.org/2001/XMLSchema#string

James W Patterson

http://www.w3.org/2001/XMLSchema#string

Mark Smolkin

http://www.w3.org/2001/XMLSchema#string

Patrice K Rehm

http://www.w3.org/2001/XMLSchema#string

Patrice Y Neese

http://www.w3.org/2001/XMLSchema#string

Priscilla Merrill

http://www.w3.org/2001/XMLSchema#string

Robyn Fink

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity.

Immunity to melanoma antigens: from self-tolerance to immunotherapy.

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

P304

4973-4980

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.17.3161

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Craig Slingluff

Kimberly A Chianese-Bullock

P577

2008-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18809608

http://www.w3.org/2001/XMLSchema#string

P932

2652084

http://www.w3.org/2001/XMLSchema#string